Educational chapters generated from checked-in OpenOnco YAML entities, source IDs, synthetic cases, and review metadata. This is not official ESMO content and does not grant CME credit.
No chapters match the current filters.
Identify the histology, germline/tumor BRCA, HRD status, and platinum-response inputs needed before first-line ovarian-cancer maintenance selection.; Explain why platinum-based induction is the universal first-line backbone and how BRCA / HRD status route the
Identify the minimum diagnostic and biomarker inputs needed before first-line DLBCL treatment selection.; Explain how IPI risk, fitness, organ function, and biology influence R-CHOP versus Pola-R-CHP reasoning.; Recognize red flags that do not switch the regim
Identify the HER2-IHC/FISH workup, organ-function baseline, and ER/PR co-status needed before HER2+ metastatic first-line treatment selection.; Explain why docetaxel + trastuzumab + pertuzumab (THP) remains the standard first-line backbone in the OpenOnco mode
Prioritize ER/PR, HER2 (including HER2-low), germline BRCA, PIK3CA, ESR1, and AKT1 status before first-line HR+/HER2- metastatic breast cancer treatment selection.; Explain why an aromatase inhibitor plus a CDK4/6 inhibitor is the standard first-line backbone,
Identify the germline / somatic HRR panel, prior-line history, and disease-burden inputs needed before mCRPC first-line treatment selection.; Explain why ARPI continuation reasoning, BRCA/HRR routing to a PARP inhibitor, and Lu-177-PSMA / cabazitaxel options s
Prioritize MSI/MMR, RAS, BRAF, HER2, sidedness, and oligometastatic status before first-line mCRC treatment selection.; Explain why MSI-H/dMMR disease takes precedence over routine chemotherapy backbones.; Recognize when RAS wild-type left-sided disease and BR
Identify the BRAF V600 status, performance status, organ function, and disease-burden inputs needed before metastatic melanoma first-line treatment selection.; Explain why dual checkpoint inhibition (nivolumab + ipilimumab) is the standard immunotherapy backbo
Explain why metastatic NSCLC first-line reasoning starts with actionable driver testing before PD-L1-only decisions.; Distinguish EGFR, ALK, ROS1, MET exon 14, RET, BRAF V600E, and NTRK driver branches from driver-negative immunotherapy branches.; Recognize PD
Use cytogenetic risk, ISS/R-ISS features, renal function, frailty, and transplant eligibility as separate first-line MM reasoning axes.; Explain why VRd and D-VRd appear as standard and alternative first-line tracks in the OpenOnco model.; Recognize myeloma em